Last updated
Thermo Fisher Scientific: Partnership
Thermo Fisher Scientific awarded UK government contract: "Supply of 2 Ion Chromatography systems" — buyer: Nuclear Restoration Services Limited
Source: find-tender.service.gov.uk
- Who
- Thermo Fisher Scientific · Biotech & Pharma · UK
- What happened
- Thermo Fisher Scientific awarded UK government contract: "Supply of 2 Ion Chromatography systems" — buyer: Nuclear Restoration Services Limited
- When
- 2026-04-09
- So what
- Alliances broaden the commercial surface, and the leadership need follows.
The leadership read
Alliances broaden the commercial surface, and the leadership need follows. Thermo Fisher Scientific's partnership in Biotech & Pharma widens demand for commercial and alliance leaders who turn an agreement into realised value. Across EMEA, watch whether dedicated senior ownership is put on it; unowned alliances quietly lapse.
Market context: Against a Talent Market Index of 109 (Hot) (up 7.3 month-on-month), EMEA is at easing (-3.1pts) on signal share.
Thermo Fisher Scientific: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 33 tracked companies; 0.1% of MitchelLake's Asia signal flow; 4 tracked across 175 days.
MitchelLake in this thematic
Also at Thermo Fisher Scientific →
More signals across Biotech & Pharma
Partnership · EMEA
Flagship Pioneering →Flagship Pioneering announced a strategic collaboration with a Lean Business Services Company to advance healthcare innovation and AI-enabled biomedical research in Saudi Arabia, leveraging national health data capabilities and precision medicine expertise to support Vision 2030.
Partnership · EMEA
UCB →UCB expanded its existing alliance with Cancer Research UK, adding two new UCB-nominated projects to advance novel cancer therapies
Capital Raising · EMEA
mbiomics →mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).
Geographic Expansion · EMEA
Bio-Techne →Bio-Techne is expanding its GMP manufacturing network with a new facility in Bristol, UK, to scale cell therapy development capabilities alongside existing North American operations.
Product Launch · EMEA
AviadoBio →AviadoBio has presented Phase 1/2 trial data for AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), showing dose-dependent increases in cerebrospinal fluid progranulin levels across four ascending doses.
Product Launch · EMEA
Biogen Inc. →Biogen announced 52-week Phase 2 results for litifilimab in cutaneous lupus erythematosus (CLE), demonstrating rapid and durable efficacy. Data supports potential first-in-class therapy positioning. Results presented at EADV 2026 Congress in Vienna. Ongoing Phase 2/3 AMETHYST study progressing.
Where this lands in our work
- Cross Border Expansion Executive Search →
Partnerships are usually the first structure a company builds before it hires locally.
- Executive Search: EMEA →
Our EMEA practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record